Background In five randomized clinical trials (RCTs), adjuvant trastuzumab (T) for early
stage breast cancer with human epidermal growth-factor receptor-2 over-expression/gene …

Background. The use of trastuzumab has proven to be a successful strategy in patients with
human epidermal growth factor receptor 2 (HER2)-positive breast cancer; however, it is …

Adjuvant trastuzumab (T) significantly reduces the risk of progression and death in HER-2
positive high-risk early breast cancer. The differential benefit of T, administered either …

Background Breast cancer is the most common cancer in women in the US and Western
Europe. Amplification of the her-2/neu gene occurs in approximately 25% of invasive ductal …

Objective: Breast cancer remains to be the globally leading female cancer. About 15% to
20% of breast cancers have human epidermal growth factor receptor 2 (HER2)-positive …

Background Trastuzumab-associated cardiotoxicity remains an issue for patients with HER2-
positive breast cancer. This pooled analysis of 3 adjuvant trials investigated the incidence …

Purpose Significant improvement in survival outcomes has been established with the
addition of trastuzumab to adjuvant chemotherapy for human epidermal growth factor …

Objective Although adjuvant trastuzumab improves survival in patients with HER2-positive
early breast cancer, there is growing concern about the long-term effect of trastuzumab …

Trastuzumab prolongs survival in women with HER2-positive breast cancer, but may
increase the risk of heart disease. The occurrence of severe cardiotoxicity, however, is not …

Background: Trastuzumab targets the human epidermal growth factor receptor 2 oncogene
and in combination with first-line therapy results in significantly improved survival outcomes …